BioSpace News Archive

Zomedica Corp. announced Larry Heaton, CEO, will present and host one-on-one meetings with investors at the Sidoti January Virtual Investor Conference, taking place on January 18-19, 2023.

TATAA Biocenter has partnered with Universal Sequencing Technology Corporation (UST) to offer full-service solutions for Long Read Sequencing Applications using UST TELL-Seq Linked Read technology.

Nanoscope Therapeutics Inc. today announced that Dr. Samarendra Mohanty , President and Chief Scientific Officer, will give a presentation titled “Pioneering a New Wave of Gene-Agnostic Gene Therapy” in the session “The Next Wave: Cell and Gene Therapy’s Commercial Shift” at Advanced Therapies Week, taking place January 17-20, 2023 in Miami.

The IMA Group (IMA) today announced it had completed the acquisition of Clinical Trials of America (CTA), a multi-therapeutic clinical trials company that brings to IMA four new independent and six embedded site locations in Louisiana and North Carolina.

Intellia Therapeutics, Inc. today announced the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has awarded the Innovation Passport for NTLA-2002, an in vivo genome editing candidate being developed for the treatment of hereditary angioedema (HAE).

Lipella Pharmaceuticals Inc. today announced top line results of the Company’s recently completed Phase 2a clinical trial evaluating the safety and efficacy of its drug candidate LP-10 for Hemorrhagic Cystitis, a rare but highly morbid disease for which there are currently no FDA approved treatments.

Celularity Inc. and CH Trading Group LLC today announced that they have entered into an exclusive distribution agreement with the Tamer Group (“Tamer”).

Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the Company has appointed Holger Lembrer as Chief Financial Officer, CFO.

CRISPR Therapeutics today announced that members of its senior management team are scheduled to participate in B. Riley Securities’ 3rd Annual Oncology Conference on Wednesday, January 18, 2023, at 10:30 a.m. ET.

VERO Biotech Inc., a commercial-stage healthcare business dedicated to neonatal intensive care and the acute care hospital community, today announced the successful close of a $30 million financing with Petrichor, a leading healthcare-dedicated growth capital provider.